↓ Skip to main content

Dove Medical Press

Article Metrics

Safinamide: an add-on treatment for managing Parkinson’s disease

Overview of attention for article published in Clinical Pharmacology : Advances and Applications, April 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
12 Mendeley
Title
Safinamide: an add-on treatment for managing Parkinson’s disease
Published in
Clinical Pharmacology : Advances and Applications, April 2018
DOI 10.2147/cpaa.s137740
Pubmed ID
Authors

Thomas Müller

Abstract

Heterogeneous expression of neurotransmitter deficits results from onset and progression of Parkinson's disease. Intervals, characterized by reappearance of motor and associated certain nonmotor symptoms, determine the end of good tolerability and efficacy of oral levodopa therapy. These "OFF" states result from levodopa pharmacokinetics and disease progression-related deterioration of the central buffering capacity for fluctuations of dopamine levels. This review discusses safinamide as an add-on therapeutic agent in orally levodopa-treated patients with "OFF" phenomena. Safinamide provided beneficial effects on "OFF" symptoms in pivotal trials with doses of 50 or 100 mg once daily. Safinamide reversibly inhibits mono-amine oxidase B and declines abnormal glutamate release by modulation of potassium- and sodium ion channels. An ideal candidate for combination with safinamide is opicapone. This inhibitor of peripheral catechol-O-methyltransferase supports continuous brain delivery of levodopa and, thus, the continuous dopaminergic stimulation concept. Both compounds with their once-daily application and good tolerability may complement each other by reduction of necessary oral levodopa intakes and "OFF" times. Thus, a promising, future option will be combination of safinamide and opicapone in one formulation. It will reduce adherence issues and may complement levodopa treatment. It will probably cause less nausea and edema than a dopamine agonist/levodopa regimen.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 25%
Student > Master 3 25%
Student > Doctoral Student 2 17%
Student > Bachelor 1 8%
Student > Postgraduate 1 8%
Other 2 17%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 33%
Unspecified 3 25%
Medicine and Dentistry 2 17%
Chemistry 1 8%
Neuroscience 1 8%
Other 1 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2018.
All research outputs
#7,365,112
of 12,768,104 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#52
of 115 outputs
Outputs of similar age
#141,022
of 273,896 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#1
of 2 outputs
Altmetric has tracked 12,768,104 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 115 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,896 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them